Is MRKR or NAMS more undervalued in 2026?

CirclFi compares Marker Therapeutics, Inc. (MRKR) and NewAmsterdam Pharma Company N.V (NAMS) using 13 institutional-grade valuation models. MRKR has a Quality of Company score of 6.1/10 while NAMS scores 2.3/10.

Which is a better buy — MRKR or NAMS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MRKR and NAMS valuations compare?

MRKR at $1.57 and NAMS at $33.68 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MRKR vs NAMS Valuation Comparison 2026 — Intrinsic Value Analysis

MRKR

Pharmaceutical Preparations

Marker Therapeutics, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$1.57

Last close

Models

9/13

Active

NAMS

Pharmaceutical Preparations

NewAmsterdam Pharma Company N.V

Quality

2.3

out of 10

Value Trap

—

Price

$33.68

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MRKR Fair Value	MRKR Upside	NAMS Fair Value	NAMS Upside
Bayesian DCF	Intrinsic	$0.86	-45.3%	$7.81	-76.8%
Earnings Power Value	Intrinsic	—	—	$18.09	-39.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.10	+33.7%	$2.99	-91.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MRKR vs NAMS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MRKR vs NAMS — Which Stock Is More Undervalued?

MRKR scores higher with a 6.1/10 quality rating vs NAMS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Marker Therapeutics, Inc. (MRKR) and NewAmsterdam Pharma Company N.V (NAMS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MRKR currently trades at $1.57 with a QOC of 6.1/10, while NAMS trades at $33.68 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).